Document |
Document Title |
JP4417838B2 |
Disclosed is a new synthetic pathway for the production of precursors for the production of compounds having general formula (8,10,12). During said synthesis, compounds of general formal (4,B) are produced in a microbiological reaction. ...
|
JP4414020B2 |
|
JP2010024238A |
To provide an enzyme inhibitor strongly inhibiting 17-hydroxylase/C17,20-lyase and 5-reductase, blocking all androgen synthesis, and useful in treatment of prostatic cancer and benign prostatic hypertrophy, based on defects associated wi...
|
JP4382735B2 |
The present invention provides a therapeutic agent for neuropathic pain having an excellent treating effect on neuropathic pain, which is an intractable disorder. More specifically, the present invention provides a therapeutic agent for ...
|
JP4368945B2 |
The invention relates to compounds of the formula : wherein : R1, R2, R3, R4 and R6 each independently represent hydrogen or a (C1-C6)alkyl, R5 is hydrogen, a (C1-C6)alkyl or a group -COR7 where R7 is a (C1-C6)alkyl, n is zero or one, an...
|
JP2009538855A |
Crystalline 11beta -(4-acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-n
or-17alpha -pregna-4,9-dien-3-one (I) and its crystalline solvates are new. Independent claims are also included for two processes for preparing (I). ACTIVIT...
|
JP4344153B2 |
|
JP4330341B2 |
There are disclosed compounds of the formula a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; which exhibit anti-inflammatory and immunodulatory activity. Also disclose...
|
JP2009167188A |
To provide a new compound having a specific strong progesterone-like property and devoid of residual androgenic activity.The compound is expressed by formula (I), wherein R1, R2, R3, R4, R5 and R6 are each a hydrogen atom or a specific s...
|
JP2009524654A |
The present invention concerns a method for the controlled precipitation of organic compounds giving crystals with a very small average size and a very narrow size distribution.
|
JP2009523434A |
The invention relates to the use of bacterial strains of the species Amycolatopsis mediterranei for the microbial transformation of 9ß,10a-steroids of general Formula (I) to their corresponding 11ß-hydroxyl analogues, as well as to spe...
|
JP4269110B2 |
The invention provides an improved process for the preparation of 17-esters of 9 alpha ,21-dihalo-pregnane-11 beta ,17 alpha -diol-20-ones, and in particular for the preparation of 17-esters of anti-inflammatory steroids according to the...
|
JP4260886B2 |
A compound having the general formula: in which: R1 is a member selected from the group consisting of —OCH3, —SCH3, —N(CH3)2, —NHCH3, —CHO, —COCH3 and —CHOHCH3; R2 is a member selected from the group consisting of halogen, ...
|
JP2009512633A |
Described herein are new retrosteroidal compounds of general formula (I), representing progesterone receptor modulators, and their production, and pharmaceutical preparations containing these compounds. Said compounds are preferably used...
|
JP4233766B2 |
A method of administering dienogest to a women in high dosages for reducing the body of the breast is described. The dosage should be at least ten times the effective dosage for inhibiting ovulation in the women. A pharmaceutical composi...
|
JP4233504B2 |
The object of the present invention is to provide vitamin D derivatives that have excellent physiological activities as medicines, particularly as therapeutic agents for skin diseases such as psoriasis, and that have a reduced hypercalce...
|
JP2009024011A |
To provide a cannabinoid receptor ligand.A compound of formula (I), a prodrug thereof or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of the prodrug, all of which exhibiting anti-inflammatory and immunom...
|
JP2009500385A |
A method of treating a subject in need of therapy for a condition involving detrimental activity of the enzyme core 2 GlcNAc-T is provided, comprising administration of a therapeutically effective amount of an inhibitor of core 2 GlcNAc-...
|
JP4187437B2 |
A compound having the structure: wherein n is an integer from 1-5; each of R1 and R2 independently is optionally substituted C1-C6 alkyl; each of W and X is independently hydrogen or C1-C6 alkyl; Y is O, S or NR3 where R3 is hydrogen, C1...
|
JP2008530129A |
The invention features charge-modified antidepressants and compounds conjugated to either a charged group or a bulky group in a manner that resists in vivo cleavage. The invention provides a method for treating a patient having an inflam...
|
JP2008530241A |
The invention is directed to methods of inhibiting the rate at which superoxide dismutse-1 (SOD) aggregates using compounds that stabilize SOD dimers. The methods are useful in the study and therapy of amyotrophic lateral sclerosis. The ...
|
JP2008527022A |
A method for the preparation of medrogestone by heterogeneously palladium- catalysed isomerisation from 17-methyl-6-methylenepregn-4-ene-3,20-dione is described.
|
JP2008120839A |
To provide a compound useful for treating mammalian diseases characterized by undesired cell mitosis.A new estradiol derivative binds to tubulin, inhibits microtubule formation or exhibits anti-mitotic properties.
|
JP2008120840A |
To provide a compound useful for treating mammalian diseases characterized by undesired cell mitosis.A new estradiol derivative binds to tubulin, inhibits microtubule formation or exhibits anti-mitotic properties.
|
JP4070297B2 |
The present invention provides a novel (meth)acrylic acid ester compound useful as a resin material for photosensitive compositions, which enables control of the molecular weight of a resin to be prepared. The novel (meth)acrylic acid es...
|
JP4066272B2 |
Methods, compositions and compounds for modulating the GABAA receptor-chloride ionophore complex to alleviate stress, anxiety, seizures, mood disorders, PMS and PND and to induce anesthesia.
|
JP2008504329A |
The present invention relates to the use of specific steroid derivatives in the preparation of medicaments for the treatment or prevention and/or amelioration of disorders relating to pathological processes in lipid rafts.
|
JP4043290B2 |
|
JP2008500282A |
The present invention provides a method of treatment of an individual with an ophthalmic condition that may comprise the step of: administering to the individual a therapeutically effective amount of a compound capable of modulating the ...
|
JP2007537131A |
Pharmaceutical compositions for and methods of preventing infection or treating an individual who has been identified as being infected with a Flavivirus, Pestivirus, picornovirus or coronavirus such as HCV, GB virus B, JEV, WNV, CSFV, B...
|
JP2007534617A |
The invention relates to the pure d-(17alpha)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-
yne-3-one-3E-oxime isomer of formula (IA), the pure d-(17alpha)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn
e-3-one-3Z-oxime isomer of fo...
|
JP4015206B2 |
A process for the production of medrogestone, in which, in an intermediate step, the solvate 3β,5α,6β-trihydroxy-6α,17α-dimethylpregnan-20-one monomethanolate is obtained as a solid, stable compound by displacing the organic solvent...
|
JP4012293B2 |
|
JP4008024B2 |
Methods and compositions for interacting with the GABAA receptor complex to induce sleep in humans using certain 5 3 alpha -hydroxy-5-reduced steroid derivatives.
|
JP2007530417A |
Provided herein are methods and compositions for modulating the activity of sirtuin deacetylase protein family members; p53 activity; apoptosis; lifespan and sensitivity to stress of cells and organisms. Exemplary methods comprise contac...
|
JP2007527381A |
The invention relates to a novel procedure for the production of a high yield of small crystalline particles of a narrow size distribution.
|
JP3983796B2 |
This invention provides a simplified method for converting pregnan-3,20-dione compounds to 3 alpha -hydroxy,3 beta -substituted-pregnanes. By selective use of reagents the unprotected dione is converted chemoselectively and diastereosele...
|
JP2007238624A |
To provide an anti-cancer phosphonate analogue, relating to compounds having anti-cancer activity. By a method and a composition which make cells accumulate or hold a biologically active medicine in them, cell targeting can be done. The ...
|
JP3977462B2 |
The invention relates to a 11-(substituted phenyl)-estra-4,9-diene derivative of formula I wherein A is a residue of a 5- or 6-membered ring containing 2 heteroatoms which are not connected to each other and independently selected from O...
|
JP3950489B2 |
PURPOSE: To obtain the subject compound used for betamethasone source material, etc., by dehydrating a 17α-hydroxy-17β-cyanoandrosta-diene-3-one to an novel intermediate, bringing a CN group to a methyl ketone and methylating after epo...
|
JP2007504273T5 |
|
JP2007514694A |
Glycosylated steroid compounds having anti-migratory activity and methods for their preparation are disclosed. Pharmaceutical compositions having an effective amount of the glycosylated steroid compounds are also disclosed. The glycosyla...
|
JP2007119500A |
To provide a method for producing 3β,5α,6β-trihydroxy-6α,17α-dimethylpregnan-20-one monomethanolate.The method for producing 3β,5α,6β-trihydroxy-6α,17α-dimethylpregnan-20-one monomethanolate comprises displacing the solvent of ...
|
JP2007512344A |
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for t...
|
JP2007508380A |
The present invention provides a method of preparing norelgestromin or norgestimate by reacting the corresponding 3-oxosteroid precursor with hydroxylamine HCl and a base to obtain a reaction mixture forming norelgestromin or norgestimat...
|
JP3902255B2 |
To provide the subject new compound having excellent antiinflammatory action and low systemic side actions and useful e.g. for an extremely strong local antiinflammatory agent by reacting deoxymethasone, etc., with an activated aromatic ...
|
JP2007504273A |
Compositions and methods involving administration of agents useful for the treatment, prevention, inhibition, etc., of fibrous adhesions.
|
JP2006528226A |
The present invention relates to methods and uses for preventing or treating hormone-dependent diseases, in particular breast cancer, in a mammal, by a combination of an progesterone-receptor antagonist, in particular the progesterone-re...
|
JP2006526025A |
Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering compounds of the general formula: wherein the variables are defined in the specification.
|
JP2006524202A |
This invention relates to 8beta-vinyl-11beta-(omega-substituted)alkyl-estra-1,3,5(10)-
trienes of general formula I with ERbeta-antagonistic activity, process for their production, their intermediate products, pharmaceutical preparations...
|